Introduction {#s1}
============

Over two-thirds of the adults in the United States are overweight or obese and over one-third of U.S. adults are obese [@pone.0038332-Weightcontrol1]. The prevalence of obesity is rising rapidly in many countries, so obesity is seen as a global pandemic. The consequences of this are not only the social and psychological effects of excessive weight, but also the significant morbidity and premature mortality associated with the serious medical conditions that obesity predisposes to, including type II diabetes, hypertension, coronary artery disease, and various forms of cancer [@pone.0038332-Calle1], [@pone.0038332-Must1].

Many risk factors, such as increased caloric intake, reduced energy expenditure, energy balance influenced by the central nervous system, adaptive thermogenesis, neuropeptides, and neurotransmitters, have been recognized to contribute to obesity [@pone.0038332-Spiegelman1]. The role of the interactions between environmental and genetic factors in the contribution to complex polygenic obesity and common obesity has been more important as no efficient treatment, apart from major surgery, currently exists [@pone.0038332-Rankinen1]. Therefore, by the discovery of novel genes or new etiological pathways, innovative therapies, preventive measures, and pharmacogenetical strategies can be found and/or used in obesity studies.

Green tea is one of the most popular beverages in the world. The impacts of green tea consumption on weight loss have been reported in clinical [@pone.0038332-Auvichayapat1], [@pone.0038332-Hsu1], [@pone.0038332-Lonac1], [@pone.0038332-Nagao1], [@pone.0038332-Phung1], [@pone.0038332-StendellHollis1], [@pone.0038332-Wang1] and laboratory animal studies [@pone.0038332-WesterterpPlantenga1]. Such an anti-obesity effect of green tea is probably due to its capacity in elevating thermogenesis and fat oxidation, lowering lipid peroxidation [@pone.0038332-Basu1], [@pone.0038332-Boschmann1], as well as suppressing appetite and nutrient absorption [@pone.0038332-Rains1]. Our previous studies suggest the positive impacts of green tea polyphenols (GTP, extracts of green tea) could be from its ability in suppressing chronic inflammation and oxidative stress damage, increasing antioxidant capacities, or estrogen-related effect [@pone.0038332-Shen1], [@pone.0038332-Shen2], [@pone.0038332-Shen3], [@pone.0038332-Shao1], [@pone.0038332-Shen4]. However, the effects of GTP on obesity along with its related mechanism(s) are not clear. We hypothesize that supplementation of GTP reduces body weight by regulating obesity related genes; and such changes are from down-regulating orexigenic genes, stimulating anorectic genes, increasing energy expenditure, suppressing proinflammatory cytokine production, and/or elevating antioxidant capacity. Therefore, the present study was designed to not only establish a reliable high-fat-induced rat model but investigate the potential benefits of GTP on body weight in these obese rats. Furthermore, the molecular mechanisms including GTP-targeted genes in regulating obesity, anti-inflammatory, anti-oxidant capacities, and estrogen-associated effects were also evaluated to advance the understanding of beneficial effects of GTP on overweight and/or obesity.

Materials and Methods {#s2}
=====================

Animals and GTP Treatments {#s2a}
--------------------------

Virgin Sprague Dawley (SD) female rats (n = 36, 3-month old, Harlan Laboratories, Indianapolis, IN, USA) were housed in an environmentally controlled animal care facility and acclimated for 5 days on an AIN-93M diet and distilled water ad libitum prior to the start of experiments. The diets were based on a modification of the AIN-93M diet and supplied by Research Diets Inc. (New Brunswick, NJ, USA). The same amount of minerals and vitamins were given to all animals.

Rats were randomized by weight into two groups: 1) control (a low-fat diet, 10% energy as fat, n = 12); or 2) a high-fat diet (HF, 45% energy as fat, n = 24) for 4 months. Animals in the control group continued on a low-fat diet for an additional 4 months (the control group). Animals in the HF diet group were randomly divided into two treatments, with (the HF+GTP group, n = 12) or without GTP (the HF group, n = 12) in drinking water, in addition to an HF diet for another 4 months. Daily food consumption was recorded. Weekly body weight was also recorded. Rats in the HF+GTP group had free access to distilled water containing 0.5% (wt/vol) GTP. GTP was purchased from the same source as that used in our previous studies (Shili Natural Product Company, Inc., Guangxi, China) with purity higher than 98.5% [@pone.0038332-Shen1], [@pone.0038332-Shen2], [@pone.0038332-Shen3], [@pone.0038332-Shao1], [@pone.0038332-Shen4]. Every 1000 mg GTP contained 464 mg (-)-epigallocatechin gallate, 112 mg (-)-epicatechin gallate, 100 mg (-)-epicatechin, 78 mg (-)-epigallocatechin, 96 mg (-)-gallocatechin gallate, and 44 mg catechin according to high-performance liquid chromatography analysis. In our previous study, we provided the same concentration of GTP (0.5%, wt/vol) in the drinking water to female rats for 20 weeks and found these was no liver damage to the studied animals as assessed by liver enzyme activity in serum [@pone.0038332-Shen5]. Rats were kept in individual stainless steel cages under a controlled temperature of 21±2°C with a 12 h light-dark cycle. All procedures were approved by the Texas Tech University Health Sciences Center Institutional Animal Care and Use Committee.

Isolation of Total RNA {#s2b}
----------------------

Rats (11 months old) were anesthetized and euthanized (not fasted), and liver samples were collected at end of the experiment. Total RNA was isolated from liver samples from the control, HF, and HF+GTP groups using an RNeasy® plus mini kit (Qiagen, Valencia, CA) following the manufacturer's protocol as described in our previous study [@pone.0038332-Shao2]. Briefly, the lysate liver sample was homogenized, genomic DNA removed, and purified. The RNA was eluted by 30 µL RNase-free water and stored at −80°C until use. The total extracted RNA was determined by measuring OD at 260 nm using a Nano-Drop 1000 Spectrophotometer (Thermo Scientific, Waltham, MA). The quality and purity of total RNA were evaluated by agarose gel electrophoresis using Horizon 11.14 (Life Technologies, Gaithersburg, MD). Total RNA samples used for RT--PCR experiments had good integrity and had OD A260/A280 ratios between 1.99--2.08 and concentration ≥45 µg/mL. The total RNA samples were further treated by DNA-free™ DNase (Applied Biosystems, Austin, TX) to remove possible DNA contamination. Three replicates, each of which were pooled sample from 3 individual rats in each group (9 rats total), were analyzed for each of the control, HF, and HF+GTP groups.

Reverse Transcription-PCR {#s2c}
-------------------------

cDNA was prepared using an RT^2^ PCR array first strand kit (SABiosciences Corporation, Frederick, MD) according to manufacturer's instructions. Briefly, 1 µg of total RNA was mixed with 2 µL of 5× gDNA elimination buffer to form a total volume of 10 µL genomic DNA elimination mixture with RNase-free H~2~O, incubated at 42°C for 5 min, and chilled on ice immediately. The mixture was then incubated with a 10 µL RT Cocktail at 42°C for 15 min, and the reaction stopped by heating at 95°C for 5 min to inactivate the reverse transcriptase. The 20 µL cDNA synthesis reaction mixture was diluted to 111 µL by adding 91 µL RNase-free H~2~O and kept on ice for further use.

Array-based SYBR® Green RT-PCR {#s2d}
------------------------------

Constitutive gene expression profiling was performed using the RT^2^ Profiler™ PCR array (SABiosciences) related to obesity signal transduction based on manufacturer's instructions. The rat genomic DNA was used first to test the array for quality control. The gene array profiled the expression of 84 genes including orexigenic genes, anorectic genes, and genes related to energy expenditure ([Table 1](#pone-0038332-t001){ref-type="table"} and [Figure 1A](#pone-0038332-g001){ref-type="fig"}, PARN-017A-12, RT^2^ Profiler™ PCR Array Rat Obesity). In addition, the array included the controls for human genomic DNA contamination, reverse transcription, positive PCR control, and 5 housekeeping genes \[ribosomal protein large P1 (Rplp1), hypoxanthine phosphoribosyltransferase 1 (Hprt1), ribosomal protein L13A (Rpl13a), lactate dehydrogenase A (Ldha), and actin beta (Actb) ([Tables S1](#pone.0038332.s001){ref-type="supplementary-material"}, [S2](#pone.0038332.s002){ref-type="supplementary-material"}, and [S3](#pone.0038332.s003){ref-type="supplementary-material"}). These 5 housekeeping genes were used in normalizing the relative gene expression for data analysis. Briefly, an aliquot of 102 µL diluted cDNA synthesis reaction was mixed with an experimental cocktail containing 1,275 µL 2× RT^2^ SYBR® green/fluorescein qPCR master mix (SABiosciences) and 1,173 µL Mili-Q water (18.3 M, pH 6.8) to form the PCR master mixture. An aliquot of 25 µL of the mixture (a total of 9.0 ng cDNA) was added to each well of the 96-well PCR array. Real-time PCR was performed using a two-step cycling program on an ABI PRISM 7000 System (Applied Biosystems) under the following conditions: 10 min at 95°C (cycle 1) followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. SYBR® green fluorescence was detected and recorded. The threshold cycle (C~T~) above the background for each reaction was calculated. The quality control using rat genomic DNA demonstrated all the targets on this PCR array were detectable as expected and ready for use ([Figure 1B](#pone-0038332-g001){ref-type="fig"}).
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###### The symbol and description of genes in the PCR array.

![](pone.0038332.t001){#pone-0038332-t001-1}

  Position     Symbol                                  Description                                                    Gene Name
  ---------- ----------- ----------------------------------------------------------------------- ----------------------------------------------------
  A01          Adcyap1                 Adenylate cyclase activating polypeptide 1                                       Pacap
  A02         Adcyap1r1           Adenylate cyclase activating polypeptide 1 receptor 1                      PACAP-R1A, PACAPR1, PACAPR1A
  A03          Adipoq                Adiponectin, C1Q and collagen domain containing                                 Acdc, Acrp30
  A04          Adipor1                           Adiponectin receptor 1                                                   --
  A05          Adipor2                           Adiponectin receptor 2                                                   --
  A06          Adra2b                        Adrenergic, alpha-2B-, receptor                                              --
  A07           Adrb1                         Adrenergic, beta-1-, receptor                                         B1AR, RATB1AR
  A08           Agrp                     Agouti related protein homolog (mouse)                                           --
  A09           Apoa4                              Apolipoprotein A-IV                                         Apo-AIV, ApoA-IV, apoAIV
  A10           Atrn                                    Attractin                                                         --
  A11           Bdnf                        Brain-derived neurotrophic factor                                         MGC105254
  A12           Brs3                            Bombesin-like receptor 3                                                  --
  B01            C3                              Complement component 3                                                   --
  B02           Calca                     Calcitonin-related polypeptide alpha                       CAL6, CGRP, Cal1, Calc, RATCAL6, calcitonin
  B03           Calcr                              Calcitonin receptor                                                    --
  B04          Cartpt                              CART prepropeptide                                                    Cart
  B05            Cck                                 Cholecystokinin                                                      --
  B06           Cckar                          Cholecystokinin A receptor                                               Cck-ar
  B07           Clps                              Colipase, pancreatic                                                   COLQ
  B08           Cnr1                         Cannabinoid receptor 1 (brain)                                             SKR6R
  B09           Cntf                           Ciliary neurotrophic factor                                                --
  B10           Cntfr                     Ciliary neurotrophic factor receptor                                            --
  B11            Crh                         Corticotropin releasing hormone                                             CRF
  B12           Crhr1                  Corticotropin releasing hormone receptor 1                                         --
  C01           Drd1a                             Dopamine receptor D1A                                            D1a, Drd-1, Drd1
  C02           Drd2                              Dopamine receptor D2                                                    --
  C03            Gal                              Galanin prepropeptide                                                  Galn
  C04           Galr1                              Galanin receptor 1                                                   Galnr1
  C05            Gcg                                    Glucagon                                                        GLP-1
  C06           Gcgr                                Glucagon receptor                                                  MGC93090
  C07            Gh1                                Growth hormone 1                                                  Gh, RNGHGP
  C08            Ghr                             Growth hormone receptor                                    GHR, BP, MGC124963, MGC156665
  C09           Ghrl                         Ghrelin/obestatin prepropeptide                                              --
  C10           Ghsr                      Growth hormone secretagogue receptor                                            --
  C11           Glp1r                       Glucagon-like peptide 1 receptor                                       Glip, RATGL1RCP
  C12           Prlhr                     Prolactin releasing hormone receptor                                       Gpr10, Uhr-1
  D01           Mchr1                   Melanin-concentrating hormone receptor 1                                 Gpr24, Mch-1r, Slc1
  D02            Grp                            Gastrin releasing peptide                                                 --
  D03           Grpr                       Gastrin releasing peptide receptor                                             --
  D04           HcRt                                   Hypocretin                                                      orexin-A
  D05          Hcrtr1                        Hypocretin (orexin) receptor 1                                             Hctr1
  D06           Hrh1                             Histamine receptor H 1                                                  Hisr
  D07           Htr2c                  5-hydroxytryptamine (serotonin) receptor 2C                             5-HT2C, 5-HTR2C, 5HT-1C
  D08           Iapp                            Islet amyloid polypeptide                                                 --
  D09           IL-1α                              Interleukin 1 alpha                                                IL-1 alpha
  D10           IL-1β                              Interleukin 1 beta                                                     --
  D11          IL-1r1                        Interleukin 1 receptor, type I                                               --
  D12           IL-6                                  Interleukin 6                                                  ILg6, Ifnb2
  E01          IL-6rα                            Interleukin 6 receptor                                           IL6R1, Il6ra, Il6r
  E02           Ins1                                    Insulin 1                                                         --
  E03           Ins2                                    Insulin 2                                                         --
  E04           Insr                                Insulin receptor                                                      --
  E05            Lep                                     Leptin                                                       OB, obese
  E06           Lepr                                 Leptin receptor                                                      Fa
  E07           Mc3r                             Melanocortin 3 receptor                                                  --
  E08            Nmb                                  Neuromedin B                                                    RGD1562710
  E09           Nmbr                              Neuromedin B receptor                                                 NMB-R
  E10            Nmu                                  Neuromedin U                                                        --
  E11           Nmur1                            Neuromedin U receptor 1                                                Gpr66
  E12            Npy                                 Neuropeptide Y                                            NPY02, RATNPY, RATNPY02
  F01           Npy1r                          Neuropeptide Y receptor Y1                                          MGC109393, NPY-1
  F02           Nr3c1                Nuclear receptor subfamily 3, group C, member 1                                 GR, Gcr, Grl
  F03           Ntrk1                Neurotrophic tyrosine kinase, receptor, type 1                                      Trk
  F04            Nts                                   Neurotensin                                                        --
  F05           Ntsr1                            Neurotensin receptor 1                                                  Ntsr
  F06           Oprk1                           Opioid receptor, kappa 1                                                  --
  F07           Oprm1                             Opioid receptor, mu 1                                           MORA, Oprm, Oprrm1
  F08          Sigmar1                  Sigma non-opioid intracellular receptor 1                                       Oprs1
  F09           Pomc                               Proopiomelanocortin                                               Pomc1, Pomc2
  F10           Ppara               Peroxisome proliferator activated receptor alpha                                     PPAR
  F11           Pparg               Peroxisome proliferator-activated receptor gamma                                      --
  F12         Ppargc1a    Peroxisome proliferator-activated receptor gamma, coactivator 1 alpha                        Ppargc1
  G01           Ptpn1               Protein tyrosine phosphatase, non-receptor type 1                               MGC93562, Ptp
  G02            Pyy                               Peptide YY (mapped)                                      GHYY, RATGHYY, Yy, peptide-YY
  G03           Ramp3           Receptor (G protein-coupled) activity modifying protein 3                                 --
  G04           Sort1                                  Sortilin 1                                                     Nt3, Nts3
  G05            Sst                                  Somatostatin                                                SS-14, SS-28, Smst
  G06           Sstr1                            Somatostatin receptor 1                                               Gpcrrna
  G07           Thrb                          Thyroid hormone receptor beta                       C-erba-beta, ERBA2, Nr1a2, RATT3REC, T3rec, TRbeta
  G08            Tnf                Tumor necrosis factor (TNF superfamily, member 2)                     MGC124630, RATTNF, TNF-alpha, Tnfa
  G09            Trh                          Thyrotropin releasing hormone                                           THR, TRH01
  G10           Trhr                     Thyrotropin releasing hormone receptor                                           --
  G11            Ucn                                    Urocortin                                                         --
  G12           Ucp1              Uncoupling protein 1 (mitochondrial, proton carrier)                        MGC108736, Ucp, Ucpa, Uncp
  H01           Rplp1                         Ribosomal protein, large, P1                                             MGC72935
  H02           Hprt1                   Hypoxanthine phosphoribosyltransferase 1                              Hgprtase, Hprt, MGC112554
  H03          Rpl13a                            Ribosomal protein L13A                                                   --
  H04           Ldha                             Lactate dehydrogenase A                                                 Ldh1
  H05           Actb                                   Actin, beta                                                       Actx
  H06           RGDC                          Rat Genomic DNA Contamination                                              RGDC
  H07            RTC                          Reverse Transcription Control                                              RTC
  H08            RTC                          Reverse Transcription Control                                              RTC
  H09            RTC                          Reverse Transcription Control                                              RTC
  H10            PPC                              Positive PCR Control                                                   PPC
  H11            PPC                              Positive PCR Control                                                   PPC
  H12            PPC                              Positive PCR Control                                                   PPC

![Rat obesity PCR Array.\
(A) Functional gene grouping in 3 colors: orexigenic genes in red, anorectic genes in yellow, and genes involved in energy expenditure in green. (B) The C~T~ value of quality control used rat genomic DNA.](pone.0038332.g001){#pone-0038332-g001}

IL-1β and IL-6 Analysis {#s2e}
-----------------------

Serum samples were collected from rats (11 months old) at end of the experiment. Serum proinflammatory cytokines IL-1β and IL-6 were analyzed by Bio-Plex™ Rat Cytokine Panel (Bio-Rad Laboratories, Inc., Hercules, CA, USA) with Luminex 100 Analyzer (Luminex Corporation, Austin, TX) following the manufacturer's instruction.

Western Blot {#s2f}
------------

The individual rat liver tissue in the control, HF, and HF+GTP groups (n = 9/group, the same samples analyzed in PCR array) was resuspended in a Radio Immuno Preciptation Assay (RIPA) lysis buffer. The samples were homogenized by sonication on ice with a sonic dismembrator (model 100, Fisher, Pittsburgh, PA). Similar to the pooling strategy used in PCR array analysis, three pooled samples were obtained in each of the control, HF, and HF+GTP groups in which an aliquot of 300 µg protein from 3 individual samples in each group was added together to form a pooled sample. Protein concentrations were measured using the Bradford protein assay (Bio-Rad Life Science, Hercules, CA). A total of 90 µg of protein from each of the pooled samples in the control, HF, and HF+GTP groups were separated by 12% SDS-polyacrylamide gel electrophoresis and then transferred to polyvinylidene fluoride (PVDF) membranes. The immobilized proteins were then incubated overnight at 4°C in blocking buffer containing 3% nonfat dry milk in 1× phosphate buffered saline (PBS) and 0.1% Tween 20 (1× PBST). After blocking, the membranes were probed with the primary antibody (anti-SOD1 or anti-COMT, Santa Cruz Biotechnology, Santa Cruz, CA) for 1 h. Antibody binding was detected with donkey anti-rabbit IgG-HRP for 1 h at room temperature. After a brief incubation with enhanced chemiluminescence, the signals on membranes were exposed to X-ray films. Relative densitometric digital analysis of protein bands were determined using Quantity One software (Bio-Rad) and normalized by the intensity of the housekeeping gene (α-Tubulin, Abcam, Cambridge, MA) for each sample.

Statistical Analyses {#s2g}
--------------------

Data are expressed as mean ± standard error (SE), unless stated. Data of body weight were analyzed by one-way analysis of variance (ANOVA) with repeated measures followed by Fisher protected least significant difference (Fisher's LSD) post-hoc tests to evaluate the effects of time and treatment. Data from RT-PCR were quantified by the ABI sequence detection software and normalized by 5 housekeeping genes (endogenous control). ΔC~T~ was defined as the value of subtracting the C~T~ value of endogenous control from the C~T~ value of the target messenger RNA (mRNA). The fold change among groups could be obtained by ΔΔC~T~. *P* value less than 0.05 based on *t*-test was used as the criteria to determine the differentially expressed genes. Data of serum biomarkers were analyzed by one-way ANOVA followed by Fisher's LSD post-hoc tests to evaluate the treatment effects. For the protein expression levels among the control, HF, and HF+GTP groups, one-way ANOVA and Tukey's post hoc tests were used to compare densitometric intensity of individual samples between groups. All analyses were performed using SPSS software (SPSS, Inc., Chicago, IL, USA) and differences with P\<0.05 were considered statistically significant.

Results {#s3}
=======

Food Intake and Body Weight {#s3a}
---------------------------

Throughout the study, the average food consumption was similar among the treatment groups (13.9±1.6, 12.8±0.6, and 12.1±1.1 g/day for the control, HF, and HF+GTP groups, respectively). The caloric intakes were 53.5±6.2, 60.5±2.8, and 57.2±5.2 kcal/day for the control, HF, and HF+GTP groups, respectively. No difference in initial body weight was seen among all treatment groups ([Figure 2](#pone-0038332-g002){ref-type="fig"}). The HF-treated group had significantly greater body weight as compared to the control group at 4 months. At the end of study, supplementation of GTP in drinking water (the HF+GTP group) significantly prevented weight gain compared to the high fat only diet (the HF group) (P\<0.05, [Figure 2](#pone-0038332-g002){ref-type="fig"}) with an order of body weight: the HF group\> the HF+GTP group  =  the control group.

![Body weight in female rats supplemented with green tea polyphenols (GTP) in drinking water for 4 months.\
Body weight (g) of the control, HF, and HF+GTP treated rats at 0--8 months. Values are mean (n = 10--12) with their standard error (SE) represented by vertical bars. \* P\<0.05 between the control and HF groups; \# P\<0.05 between the HF and HF+GTP groups; ∧P\<0.01 between the control and HF+GTP groups.](pone.0038332.g002){#pone-0038332-g002}

Gene Expression Alterations {#s3b}
---------------------------

The triplicate samples from each group produced reproducible results. A total of 35 genes (as measured by C~T~ value) were assigned as undetectable in all groups, leaving 49 genes detected ([Tables S1](#pone.0038332.s001){ref-type="supplementary-material"}, [S2](#pone.0038332.s002){ref-type="supplementary-material"}, and [S3](#pone.0038332.s003){ref-type="supplementary-material"} and [Figure 3A](#pone-0038332-g003){ref-type="fig"}). Relative to the control group, the HF group significantly decreased expression of 11 genes \[adenylate cyclase activating polypeptide 1 (pituitary) receptor 1 (Adcyap1r1), adrenergic beta-1-receptor (Adrb1), agouti related protein homolog (Agrp), apolipoprotein A-IV (Apoa4), ciliary neurotrophic factor receptor (Cntfr), growth hormone receptor (Ghr), ghrelin/obestatin prepropeptide (Ghrl), insulin 1 (Ins1), leptin receptor (Lepr), nuclear receptor subfamily 3 group C member 1 (Nr3c1), and sortilin 1 (Sort1)\] and increased that of interleukin 1 beta (IL-1β) (P\<0.05, [Figure 3B](#pone-0038332-g003){ref-type="fig"}). Supplementation of GTP to drinking water (the HF+GTP group) significantly reverted the gene expression levels of IL-1β and Ins1 compared to those of the non-supplemented group (the HF group) (P\<0.05, [Figure 3C](#pone-0038332-g003){ref-type="fig"}). In addition, the gene expression of interleukin 6 receptor alpha (IL-6rα) was significantly increased in the HF+GTP group compared to the HF group (P\<0.05, [Figure 3C](#pone-0038332-g003){ref-type="fig"}). Finally, Nr3c1 was the only gene showing significantly down-regulation in the HF+GTP group as compared to the control group (P\<0.05, [Figure 3D](#pone-0038332-g003){ref-type="fig"}).

![The changes of obesity-related genes among the control, HF, and HF+GTP groups.\
(A) Representative PCR array gene tables of undetected genes and detected genes. (B) The heat map demonstrating fold regulation expression data between the HF group and the control group. Genes with significant differences between two groups are shown in the histogram. (C) The heat map demonstrating fold regulation expression data between the HF+GTP group and the HF group. Genes with significant differences between two groups are shown in the histogram. (D) The heat map demonstrating fold regulation expression data between the HF+GTP group and the control group. Genes with significant differences between two groups are shown in the histogram.](pone.0038332.g003){#pone-0038332-g003}

Blood Analysis {#s3c}
--------------

The serum levels of IL-1β and IL-6 in the control, HF, and HF+GTP groups are shown in [Figure 4](#pone-0038332-g004){ref-type="fig"}. In comparison to the control group or the HF+GTP group, the HF group had the highest serum IL-1β and IL-6 concentrations while the HF+GTP group had the lowest serum IL-1β and IL-6 concentrations. Compared to the HF group, 4-month GTP supplementation to the HF diet (the HF+GTP group) caused a significant decrease of serum proinflammatory cytokines including IL-1β and IL-6 (P\<0.05, [Figure 4](#pone-0038332-g004){ref-type="fig"}).

![Proinflammatory cytokines changes among the control, HF, and HF+GTP groups.\
Results are expressed as mean±SE. \# P\<0.05 between the HF and HF+GTP groups.](pone.0038332.g004){#pone-0038332-g004}

Western Blot Analyses of SOD1 and COMT Protein Expression {#s3d}
---------------------------------------------------------

The relative protein expression levels of SOD1 and COMT are shown in [Figure 5](#pone-0038332-g005){ref-type="fig"}. SOD1 expression level was significantly decreased in the HF group as compared to the control group (P\<0.01, [Figure 5A](#pone-0038332-g005){ref-type="fig"}). On the other hand, SOD1 expression level was significantly increased in the HF+GTP group as compared to either HF or control groups (P\<0.01, [Figure 5A](#pone-0038332-g005){ref-type="fig"}). The expression level of COMT was significantly decreased in the HF group as compared to the control group (P\<0.05, [Figure 5B](#pone-0038332-g005){ref-type="fig"}).

![Western blot analyses of protein expression in the control, HF, and HF+GTP groups.\
(A) Effects of HF and HF+GTP treatment on the protein expression of SOD1. (B) Effects of HF and HF+GTP treatment on the protein expression of COMT. Blots were also probed for α-tubulin to confirm equal protein loading. The relative protein intensities of SOD1 and COMT were compared with the intensity of α-tubulin. The intensity of each band was quantified using Quantity One software. Data are means±SE, n = 3. The experiments were conducted in triplicate. \* P\<0.05 between the control and HF groups; \*\* P\<0.01 between the control and HF groups; \#\# P\<0.01 between HF and HF+GTP; ∧∧P\<0.01 between the control and HF+GTP groups.](pone.0038332.g005){#pone-0038332-g005}

Discussion {#s4}
==========

Numerous studies in genetic, metabolic, hormonal, behavioral, social, and cultural aspects have been conducted to increase our understanding of the cause and treatment of obesity [@pone.0038332-Must1], [@pone.0038332-Spiegelman1], [@pone.0038332-Khan1], [@pone.0038332-Jequier1], [@pone.0038332-Dulloo1]. The physiological and molecular changes observed in this high-fat-induced obese rat model provide a useful insight into the development of obesity in humans. In the study, we also measured % fat mass in the animals using the ImpediVET™ Bioimpedance Spectroscopy device (ImpediMed Limited, Brisbane, Australia) at the beginning and the end of study. There was no difference in % fat mass among the groups at the baseline (21.51±0.97, 21.16±1.10, and 23.61±0.83 for the control, HF, and HF+GTP groups, respectively). At the end of study, the order of % fat mass was the HF group (31.36±0.82) \> the HF+GTP group (27.78±0.79)  =  the control group (25.78±0.76). Consistent with other reports of obesity models [@pone.0038332-Buettner1], [@pone.0038332-Dobrian1], obese rats by a HF diet resulting in a significant increase in % fat mass indicates the difference in body weight was due to mainly the increased fat mass.

In the present study, we have shown that a number of genes involved in obesity changed in HF-treated rats, which further demonstrated the usefulness of this rat model. In addition, our results showed the reduced and controlled weight due to the anti-obesity activity of GTP supplementation. This beneficial effect could be a result of GTP-induced alteration of obesity related genes, anti-inflammation activity, anti-oxidative stress capacity, as well as estrogen-like actions which in turn regulate appetite, metabolism, or absorption of calories.

A total of 12 obesity-related genes showed significant changes in the HF-treated obese rats as compared to those of the control. Among these, Adcyap1r1, Adrb1, Agrp, Apoa4, Cntfr, Ghr, Ghrl, Ins1, Lepr, Nr3c1, and Sort1 decreased significantly while IL-1β increased significantly in the HF group in comparison with those in the control group. There is considerable evidence that these genes play three critical roles in the pathogenesis of obesity, including orexigenic function, anorectic function, and energy expenditure.

Agrp, Ghrl, and Nr3c1 are classified as orexigenic genes. Agrp is one of the most potent and long-lasting of appetite stimulators [@pone.0038332-Ollmann1], [@pone.0038332-Shutter1]. The appetite stimulating effects of Agrp are inhibited by the hormone leptin (higher in the HF group than the control group, data not shown) and activated by the hormone ghrelin (Ghrl, lower in the HF group than the control group). Ghrelin (Ghrl) is the endogenous ligand for the growth hormone secretagogue receptor (GHSR) for maintaining growth hormone (GH) release and energy homeostasis [@pone.0038332-Kojima1]. Previous studies have demonstrated the decreased level of circulating ghrelin in humans with obesity [@pone.0038332-Tschop1], [@pone.0038332-Cummings1]. Similarly, Nr3c1, the glucocorticoid receptor gene, has been reported to be involved in hyperinsulinaemia, fat deposition, and inflammatory responses associated with obesity [@pone.0038332-Rosmond1]. Nr3c1 mRNA levels have also been reported to be significantly decreased in obesity [@pone.0038332-BoulluCiocca1], [@pone.0038332-Bronnegard1].

Apoa4, Cntf, Ghr, IL-1β, Ins1, Lepr, and Sort are anorectic genes. Apolipoprotein (Apoa4 or Apo A-IV), activated through a dietary fat-elicited satiety signal [@pone.0038332-Fujimoto1], [@pone.0038332-Fujimoto2], is involved in various activities, such as antioxidant activity, cholesterol transporter activity, lipid binding, phosphatidylcholine binding [@pone.0038332-Waiman1], [@pone.0038332-Wong1], [@pone.0038332-Navab1]. Therefore, the decreased gene expression level of Apoa4 in the HF group could contribute to diet-induced obesity. Cntfr can mimic the biological actions of leptin while overcoming "leptin resistance" [@pone.0038332-Matthews1]. Ghr has profound effects on adipogenesis, lipogenesis and lipolysis by inducing alterations in the central nervous system [@pone.0038332-Nam1], [@pone.0038332-Ballesteros1]. Studies have suggested that decreased Ghr availability could result in obesity [@pone.0038332-Egecioglu1], [@pone.0038332-Erman1]. Insulin, which plays important roles in regulating carbohydrate and fat metabolism in the body, is commonly deficient or resistant in obese patients [@pone.0038332-Kahn1]. The decreased gene expression level of Ins1 in the HF group further supports this rat obese model. Leptin is one of the most important adipose derived hormones, which secretes into the bloodstream and is transported to the brain, where it stimulates or inhibits release of several neurotransmitters [@pone.0038332-Brennan1], [@pone.0038332-Houseknecht1], [@pone.0038332-Houseknecht2]. In line with our findings, lepr and subsequent signaling events have been reported to be down-regulated in the liver of dietary-induced obese rats [@pone.0038332-Brabant1]. Finally, sortilin exhibits the strongest association with serum lipoproteins by degrading nascent VLDL particles [@pone.0038332-Musunuru1], [@pone.0038332-Teslovich1].

Adcyap1r1 and Adrb1 are the two genes that relate to energy expenditure. Adcyap1r1 can influence the control of energy homeostasis and has remarkable anti-inflammation action [@pone.0038332-Elekes1], [@pone.0038332-Garfield1]. Adrb1 induces lipolysis in adipose tissue [@pone.0038332-Gjesing1]. In all, the altered expression levels of 12 obesity genes in the HF group, as compared to the control group, suggest a qualified obese model, which could result in reverted obesity via regulating the expression of obesity-related genes. The obesity model used in our study may more closely simulate the onset of obesity in humans, rather than the genetic alteration or mutation induced obesity models.

The findings that GTP supplementation into the drinking water reversed the expression levels of 11/12 genes (except Nr3c1) in obese rats corroborates the anti-obesity role of GTP. For instance, our findings of increased Adcyap1r1 and Adrb1 after GTP treatment are in agreement with studies, demonstrating that green tea increases energy expenditure [@pone.0038332-Rumpler1], [@pone.0038332-Dulloo2], [@pone.0038332-Chantre1], and has proved effective in reducing body fat partially mediated via Adrb1 activation [@pone.0038332-Choo1].

Chronic systemic inflammation directly contributes to the development of obesity [@pone.0038332-Rankinen1], [@pone.0038332-Elekes1]--[@pone.0038332-Rumpler1]. For instance, overweight and obese women generally have elevated serum levels of inflammation cytokines, such as IL-6 and TNF-α [@pone.0038332-Yudkin1], [@pone.0038332-Festa1], [@pone.0038332-Cottam1]. Therefore, suppressing chronic inflammation may be a good strategy to prevent and/or treat obesity. The observations that the HF group increased IL-1β gene expression agrees with Matsuki *et al.* that IL-1β is harmful for the energy homeostasis of the body through its role in lipid metabolism by regulating insulin levels [@pone.0038332-Matsuki1]. GTP supplementation suppressed the chronic inflammation due to a high-fat diet in the present study, as shown by decreased IL-1β gene expression and circulating IL-1β and IL-6 levels, as well as increased IL-6rα and Inl1 gene expression. However, although higher expression levels of IL-1β and IL-6 in the serum from rats of the HF group were observed as compared to those of the control, these differences did not reach statistical significances. This might due to the large variations within the groups. Therefore, future studies using a larger sample size are warranted.

One of the other most widely recognized characteristics of obesity is the increased oxidative stress [@pone.0038332-BondiaPons1]. GTP has shown its anti-oxidant activities, stemming from its ability to scavenge reactive oxygen species [@pone.0038332-Moon1]. In the present study, GTP supplementation increased SOD1 expression (an indicator of antioxidant capacity) in obese rats. Our results are consistent with the anti-obesity role of GTP by increasing antioxidant capacity and/or decreasing oxidative stress damage, which is commonly observed in obesity [@pone.0038332-Shao1], [@pone.0038332-Khan1], [@pone.0038332-Furukawa1], [@pone.0038332-Keaney1], [@pone.0038332-Wolfram1].

Although there was no statistically significant difference in COMT protein expression between the HF+GTP group and the HF group due to the large variation, this restoration of COMT made no statistical significance between HF+GTP and control groups. COMT activity is important in fat regulation, since preadipocyte proliferation and differentiation can be inhibited by 2-methoxyestradiol, the synthesis of which is catalyzed by COMT [@pone.0038332-Pico1]. Weight loss results in a reduction in circulating estrogens [@pone.0038332-Berrino1], [@pone.0038332-Tchernof1]. Therefore, the restoration of COMT expression observed after GTP treatment would inhibit the activation of estrogen by catalyzing the methylation of catechol estrogens to less active methoxy estrogens (e.g., 2-methoxyestradiol). Moreover, COMT has been shown to be involved in reward-motivated behaviors such as development of diet-induced obesity through metabolizing dopamine [@pone.0038332-Wang2]. Taken together, the GTP-induced weight loss may possibly and partially result from increased COMT through its regulation of estrogen and appetite.

Among all the 84 genes related to obesity, a total of 35 genes were not detected in all 3 groups of our rat liver samples. There might be reasons such as genes are not (or very weakly) expressed in the liver tissues, for example Brs3, which is normally expressed in the brain, kidney, and testis. Calcr is normally expressed in the brain and kidney. Cartpt can be detected in the brain, spinal cord, prostate, and testis but not in the liver [@pone.0038332-Genecards1]; and the detection sensitivity of gene array is limited. On the other hand, due to the mixture of cell types in tissue samples, the magnitude of expression changes of some genes might not be detected.

Studies including ours have demonstrated the effects of green tea on weight loss. Possible mechanisms behind this may result from the observation of lower serum and LDL cholesterol, increased HDL cholesterol, and lower serum glucose [@pone.0038332-Mitscher1], [@pone.0038332-Kao1], [@pone.0038332-Matsumoto1]; the increase in fat mobilization and oxidation [@pone.0038332-Boschmann1], [@pone.0038332-Rains1], [@pone.0038332-Klaus1], [@pone.0038332-Murase1]; the increase in energy expenditure [@pone.0038332-Borchardt1] and appetite suppression [@pone.0038332-Belza1], [@pone.0038332-Belza2]; as well as the reduction in the absorption of nutrients [@pone.0038332-Hsu2] as a result of GTP treatment. However, there are still debates of the overall effects of GTP that show some inconsistent results [@pone.0038332-Chan1], [@pone.0038332-Fukino1], [@pone.0038332-Diepvens1], [@pone.0038332-Hill1]. For instance, several studies have failed to show differences in assessed subjective appetite or energy intake after green tea consumption, despite favorable outcomes for body weight and body fat [@pone.0038332-Auvichayapat1], [@pone.0038332-Wang1], [@pone.0038332-Maki1]. These might partially due to the variation and/or the sensibility of detecting small changes in dietary intake, which are hard to be accurately measured with available techniques. As an outcome, this minor imbalance between energy intake and energy expenditure over years may lead to severe obesity. In fact, in lines with these findings, the correlation between the changes of orexigenic genes and the behavior of appetite was not observed in our current study. Collectively, this could lead to the difficulty in assessing the etiology of obesity as well as the protective effects of GTP supplement. Nevertheless, our study firstly demonstrated the changes of anorectic and/or orexigenic genes in the obese rat, while GTP supplement could reverse the effects of these genes. The study strategy conducted in the present study could provide an additional concept in assessing not only the etiologic mechanisms of obesity but the beneficial effects of GTP. However, this study is limited in lacking a control+GTP group which would provide additional evidences to demonstrate the beneficial effects of GTP supplement. In addition, the study using male mice could be helpful in expanding the findings of the present study to better understand the protective effects of GTP supplement in obesity.

In summary, our data demonstrated that GTP supplementation has potent effects on body weight in obese middle-aged female rats through regulating obesity-related genes, anti-inflammation activity, anti-oxidative stress capacity, as well as estrogen-associated actions. We believe that our study presents a critical first step towards evaluating the effects of green tea consumption in obese middle-aged women. Translational research based on findings from animal observations to investigate possible therapeutic efficacy of GTP on obese women will be worthy in a future study.
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